Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

KaloBios Pharmaceuticals Company Profile (NASDAQ:KBIO)

Consensus Ratings for KaloBios Pharmaceuticals (NASDAQ:KBIO) (?)
Ratings Breakdown: 1 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $5.83 (202.25% upside)

Analysts' Ratings History for KaloBios Pharmaceuticals (NASDAQ:KBIO)
Show:
DateFirmActionRatingPrice TargetDetailsShare
7/2/2014ZacksUpgradeNeutral -> Outperform$2.50ViewTweet This Rating  Share This Rating on StockTwits
2/27/2014JMP SecuritiesInitiated CoverageOutperform$8.00ViewTweet This Rating  Share This Rating on StockTwits
1/30/2014Needham & Company LLCDowngradeBuy -> HoldViewTweet This Rating  Share This Rating on StockTwits
1/30/2014Leerink SwannLower Price Target$15.00 -> $7.00ViewTweet This Rating  Share This Rating on StockTwits
3/5/2013Needham & Company LLCInitiated CoverageBuy$11.00ViewTweet This Rating  Share This Rating on StockTwits
2/26/2013Leerink SwannInitiated CoverageOutperform$15.00ViewTweet This Rating  Share This Rating on StockTwits
2/26/2013William BlairInitiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2012 forward)